A Phase 2 interventional study of Ravaglimab and Ravagalimab in Sjogren's Syndrome (SS), sponsored by AbbVie. Withdrawn at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-02-01.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Sjogren's Syndrome with a site in Netherlands — 3 open to participants now, 5 under way, 3 of them phase 3. Sjogren's Syndrome · Netherlands.
Among the 18 studies in Sjogren's Syndrome with a site in Netherlands, this one is the 18th largest by enrollment, is one of 2 that started in 2020, is one of 9 in phase 2, and was the 9th registered.
330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.
Browse Sjogren's Syndrome studies →3 of the 18 studies in Sjogren's Syndrome with a site in Netherlands are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Netherlands, United States, Australia and 6 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in Netherlands, United States, Australia and 17 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Netherlands, United States, Belgium and 3 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 4
First in 2000; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 120 across the 18 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 8 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 2 studies filed under Sjogren's Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Sjogren's Syndrome with a site in Netherlands that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05946941Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | 2026-11-18 |
| NCT06741969Phase 3Janssen Research & Development, LLCNipocalimab in Moderate to Severe Sjogren's Disease | 2027-02-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Sjogren's Syndrome with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sjogren's syndrome (SS) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement. In addition, a variety of systemic manifestations may occur; including fatigue, musculoskeletal symptoms, rashes, and internal organ (e.g., pulmonary, renal, hepatic, and neurologic) disease. Sjogren's syndrome may occur in isolation, primary Sjogren's syndrome (pSS), or in a secondary form, often associated with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), or systemic sclerosis. Ravagalimab is an investigational drug being developed to help treat patients with inflammatory diseases like SS. This study will evaluate how well ravagalimab works within the body and how safe it is in patients with primary SS (pSS).
Ravagalimab, a potent CD40 antagonist is an investigational drug being developed for the treatment of Sjogren's syndrome (SS). This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given which study drug. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. Participants 18-75 years of age with Sjogren's syndrome (SS) will be enrolled. Around 45 participants will be enrolled in the study in multiple sites within Netherlands.
Participants will receive ravagalimab intravenous (IV) loading dose or IV placebo at baseline followed by subcutaneous (SC) ravagalimab or matching placebo for 22 weeks.
There will be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, labial gland (lip) biopsy, and checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a loading dose of intravenous (IV) ravagalimab dose A at Week 0 followed by subcutaneous (SC) ravagalimab dose A every other week (eow)
Drug: Ravaglimab · Drug: Ravagalimab
Participants will receive a loading dose of intravenous (IV) placebo at Week 0 followed by subcutaneous (SC) placebo every other week (eow)
Drug: Placebo
Intravenous Injection
Also known as: ABBV-323
Subcutaneous Injection
Also known as: ABBV-323
Intravenous Injection
Subcutaneous Injection
Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)
ESSDAI is a systemic disease activity index including 12 domains (i.e., organ systems: cutaneous, respiratory, renal, articular, muscular, peripheral nervous system, central nervous system, haematological, glandular, constitutional, lymphadenopathic and biological).
Time frame: Week 24
Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)
ESSDAI is a systemic disease activity index including 12 domains (i.e., organ systems: cutaneous, respiratory, renal, articular, muscular, peripheral nervous system, central nervous system, haematological, glandular, constitutional, lymphadenopathic and biological).
Time frame: Up to Week 16
Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI)
ESSPRI is designed to evaluate the patient symptoms with 3 questions related to the dryness, pain and fatigue a participant has experienced in the prior 2 weeks. It is a numeric rating scale from 0 - 10, with a final score the mean of the 3 questions
Time frame: Up to Week 24
Change From Baseline in Tender Joint Count
An assessment of 68 joints will be done for tenderness by pressure manipulation on physical examination. Joint pain/tenderness will be classified as: present, absent, replaced or no assessment.
Time frame: Up to Week 24
Change From Baseline in Swollen Joint Count
An assessment of 66 joints will be done by directed physical examination. The joints to be examined for swelling are the same as those examined for tenderness, except the hip joints are excluded. Joint swelling will be classified as present, absent, replaced or no assessment.
Time frame: Up to Week 24
Change From Baseline in Salivary Flow (Unstimulated)
Patients will be asked to collect their saliva in a cup every 30 seconds for a total period of 5 minutes. The saliva production is expressed in ml/minute.
Time frame: Up to Week 24
Change From Baseline in Salivary Flow (Stimulated)
Saliva production is stimulated by parafilm and collected in a cup every 30 seconds for a total period of 5 minutes.. The saliva production is expressed in ml/minute.
Time frame: Up to Week 24
Change From Baseline in Lacrimal Flow (Schirmer's Test of Ocular Function)
Lachrymal flow will be assessed by Schirmer's test of ocular function. A small filter paper will be placed in the conjunctival sac for 5 minutes. After that, the degree of wetting is evaluated
Time frame: Up to Week 24
Change From Baseline in Van Bijsterveld Score
The van Bijsterveld score is an ocular score for dryness. The Bijsterveld score is determined by adding up the combined score (from 0 to 3; 0 is normal and 3 is the highest level of staining) in the central and two outer sections of the eye.
Time frame: Up to Week 24
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
FACIT-Fatigue is a 13-item questionnaire that evaluates fatigue/tiredness and its impact on daily activities and functioning in chronic diseases. This instrument includes items such as tiredness, weakness, listlessness, lack of energy, and the impact of these feelings on daily functioning (e.g., sleeping, and social activities). A lower score indicates less negative impact on daily activities.
Time frame: Up to Week 24
Change From Baseline in Patient's Global Assessment of Disease Activity Numeric Rating Scales
Patient's Global Assessment of Disease Activity Numeric Rating Scale allows a patient to score 0 - 10 to assess the patient's overall functionality assessment considering the disease activity within the past week
Time frame: Up to Week 24
Change From Baseline in Physician's Global Assessment of Disease Activity Numeric Rating Scales
Physician's Global Assessment of Disease Activity Numeric Rating Scale allows a physician to score 0 - 10 to assess the patient's overall functionality assessment considering the disease activity within the past week.
Time frame: Up to Week 24
Change from Baseline in anti-Sjogrens-syndrome-related antigen A (anti-SSA)
Change from baseline in anti-SSA s assessed.
Time frame: Up to Week 24
Change from Baseline in anti-Sjogrens-syndrome-related antigen B (anti-SSB)
Change from baseline in anti-SSB is assessed.
Time frame: Up to Week 24
Change from Baseline in antinuclear antibody (ANA)
Change from baseline in antinuclear antibody (ANA) is assessed.
Time frame: Up to Week 24
Change from Baseline in rheumatoid factor (RF)
Change from baseline in rheumatoid factor (RF) is assessed.
Time frame: Up to Week 24
Change from Baseline in high-sensitivity C-reactive protein (hsCRP)
Change from baseline in high-sensitivity C-reactive protein (hsCRP) is assessed.
Time frame: Up to Week 24
Change from Baseline in immunoglobulin M (IgM)
Change from baseline in immunoglobulin M (IgM) is assessed
Time frame: Up to Week 24
Change from Baseline in immunoglobulin M (IgG)
Change from baseline in immunoglobulin M (IgG) is assessed.
Time frame: Up to Week 24
Change from Baseline in immunoglobulin A (IgA)
Change from baseline in immunoglobulin A (IgA) is assessed.
Time frame: Up to Week 24
Change from Baseline in Serum-Free Light Chains
Change from baseline in serum-free light chains is assessed.
Time frame: Up to Week 24
Change from Baseline in Serum C3
Change from baseline in Serum C3 is assessed.
Time frame: Up to Week 24
Change from Baseline in Serum C4
Change from baseline in Serum C4 is assessed.
Time frame: Up to Week 24
Change from Baseline in Haemolytic Complement CH50
Change from baseline in CH50 is assessed.
Time frame: Up to Week 24
Change From Baseline in Focus Score of Sublabial Salivary Gland Biopsy (In Participants With a Screening and Week 24 Biopsy)
Change from baseline in focus score of sublabial salivary gland biopsy is assessed.
Time frame: Week 24
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
No publications or documents are linked to this record.
Start is estimated for Mar 2020; primary completion for Apr 2022, 25 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravagalimab